| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 611.53 KB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
This thesis aims to identify value creation for all participants in M&A deals in the healthcare
industry between 1981 and 2021.
On average, M&A transactions in the healthcare industry lead to positive abnormal returns for
target firms shareholders and for the combined entities.
Furthermore, we analyse the key drivers. For targets’ shareholders, we find positive
significant impact in the acquiring company size (market capitalisation) and in the target
R&D intensity (as a percentage of target enterprise value). For the hypothetical combined
entity, we observe a positive significant impact in the deal size (as a percentage of acquirer
enterprise value).
Descrição
Palavras-chave
M&A Healthcare Pharmaceutical industry Medtech Biotechnology
